Hospital
Hma Santa Rosa Medical Center LLC
Hma Santa Rosa Medical Center LLC was paid $11.11M by Medicaid between Jan 2018 and Dec 2024, across 205 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoHMA SANTA ROSA MEDICAL CENTER LLC
MILTON, FL 32570
MILTON, FL 32570
33aNPI1528015302assigned 05/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.11M
24GClaims540,887
24DCodes billed205
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#45 of 163
Median peer was paid$4.77M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,397 | $596K | |
| 2019 | 106,926 | $1.69M | |
| 2020 | 88,731 | $1.39M | |
| 2021 | 110,659 | $2.16M | |
| 2022 | 113,260 | $2.65M | |
| 2023 | 66,894 | $1.84M | |
| 2024incomplete | 23,020 | $786K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 36,885 | 32,607 | $2.54M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 23,008 | 19,190 | $1.45M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.6% | 11,052 | 10,121 | $849K |
| 36415 | Collection of venous blood by venipuncture | 7.6% | 35,776 | 26,551 | $842K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6.5% | 9,023 | 8,296 | $727K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 2,858 | 2,518 | $497K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 4,134 | 3,368 | $491K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.1% | 3,386 | 2,890 | $452K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.1% | 6,971 | 5,759 | $350K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.9% | 4,793 | 4,108 | $326K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 4,115 | 1,118 | $223K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.9% | 15,707 | 14,707 | $215K |
193 more codes
| 99285 | Emergency room visit (most serious) | 1.3% | 4,324 | $147K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,308 | $96K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 442 | $72K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,547 | $65K |
| 80053 | Comprehensive metabolic panel | <1% | 26,891 | $60K |
| 73610 | <1% | 1,345 | $60K | |
| 81003 | <1% | 8,415 | $57K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,857 | $56K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,532 | $55K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,191 | $55K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,023 | $52K |
| 81001 | <1% | 9,961 | $50K | |
| 82962 | <1% | 4,481 | $45K | |
| 87428 | <1% | 13,345 | $45K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 600 | $44K |
| 73630 | <1% | 1,722 | $42K | |
| 81025 | <1% | 5,887 | $40K | |
| 86901 | <1% | 1,039 | $40K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,504 | $37K |
| 73130 | <1% | 1,142 | $35K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,597 | $34K |
| G0378 | Hospital observation service, per hour | <1% | 3,485 | $33K |
| 73110 | <1% | 892 | $33K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,881 | $32K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,097 | $31K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,642 | $29K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,261 | $28K |
| 74018 | <1% | 1,749 | $28K | |
| 87420 | <1% | 1,164 | $25K | |
| 73564 | <1% | 1,192 | $25K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,142 | $24K |
| 85610 | <1% | 4,763 | $23K | |
| 97162 | <1% | 241 | $22K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 962 | $22K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 721 | $20K |
| 73030 | <1% | 1,107 | $19K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 334 | $18K |
| 72110 | <1% | 701 | $18K | |
| 84484 | <1% | 7,018 | $18K | |
| 59025 | Fetal non-stress test | <1% | 750 | $17K |
| 86900 | <1% | 393 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,219 | $16K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,503 | $16K |
| 97597 | <1% | 412 | $15K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 967 | $14K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 71 | $14K |
| 94060 | <1% | 395 | $14K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,708 | $14K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 527 | $13K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,042 | $12K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 167 | $12K |
| 83690 | <1% | 11,532 | $12K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,527 | $12K |
| 76801 | <1% | 615 | $11K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,089 | $11K |
| 87070 | <1% | 1,014 | $10K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,582 | $10K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 123 | $10K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,479 | $10K |
| 83880 | <1% | 4,130 | $9K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 169 | $9K |
| 85730 | <1% | 4,447 | $9K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 130 | $9K |
| 96376 | <1% | 2,556 | $8K | |
| 93975 | <1% | 582 | $8K | |
| 83735 | <1% | 3,237 | $8K | |
| 73080 | <1% | 298 | $8K | |
| 71250 | <1% | 163 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,178 | $7K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,873 | $7K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,857 | $7K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,524 | $7K |
| 87040 | <1% | 4,159 | $6K | |
| 93971 | <1% | 422 | $6K | |
| 80061 | Lipid panel | <1% | 4,476 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,761 | $5K |
| 73140 | <1% | 179 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,397 | $5K |
| 82550 | <1% | 3,073 | $4K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 154 | $4K |
| 84439 | <1% | 2,151 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 861 | $4K |
| 87186 | <1% | 2,066 | $4K | |
| 97161 | <1% | 57 | $4K | |
| 87077 | <1% | 2,596 | $4K | |
| 70486 | <1% | 64 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,109 | $3K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,592 | $3K |
| 85027 | <1% | 2,146 | $3K | |
| 76641 | <1% | 46 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 468 | $3K |
| 87807 | <1% | 464 | $3K | |
| 87210 | <1% | 704 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,218 | $3K |
| 12001 | <1% | 96 | $2K | |
| 83605 | <1% | 2,433 | $2K | |
| 93017 | <1% | 121 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 45 | $2K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 39 | $2K |
| 73502 | <1% | 240 | $2K | |
| 80076 | <1% | 514 | $2K | |
| 87081 | <1% | 13,242 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 219 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 682 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,063 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,714 | $2K |
| 82607 | <1% | 954 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 339 | $1K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 26 | $1K |
| 95819 | <1% | 13 | $1K | |
| 10060 | <1% | 40 | $1K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 27 | $1K |
| 87220 | <1% | 546 | $1K | |
| 84702 | <1% | 1,377 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 596 | $852.86 |
| 73090 | <1% | 98 | $834.76 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,743 | $778.72 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,023 | $711.45 |
| 80320 | <1% | 496 | $708.75 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 39 | $686.56 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 210 | $667.82 |
| 85379 | <1% | 1,085 | $581.80 | |
| 70220 | <1% | 12 | $535.73 | |
| 83970 | <1% | 64 | $483.88 | |
| 94727 | <1% | 446 | $483.29 | |
| 86850 | <1% | 385 | $475.84 | |
| 72050 | <1% | 24 | $469.95 | |
| 86140 | <1% | 449 | $444.79 | |
| J1245 | Injection, dipyridamole, per 10 mg | <1% | 13 | $438.96 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 71 | $438.96 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 861 | $431.26 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 579 | $393.50 |
| 84100 | <1% | 234 | $386.77 | |
| 80306 | <1% | 215 | $317.96 | |
| 70360 | <1% | 15 | $288.85 | |
| 73560 | <1% | 28 | $281.57 | |
| 86703 | <1% | 405 | $270.37 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $265.83 |
| 84703 | <1% | 2,335 | $246.44 | |
| G1002 | Clinical decision support mechanism medcurrent, as defined by the medicare appropriate use criteria program | <1% | 135 | $217.69 |
| 86592 | <1% | 266 | $215.98 | |
| 73590 | <1% | 29 | $208.94 | |
| 12011 | <1% | 12 | $201.67 | |
| 82553 | <1% | 1,062 | $193.11 | |
| 97116 | <1% | 15 | $192.87 | |
| 85651 | <1% | 462 | $184.45 | |
| 82728 | <1% | 526 | $183.14 | |
| 90714 | <1% | 13 | $172.57 | |
| 82270 | <1% | 12 | $153.39 | |
| 82746 | <1% | 387 | $137.92 | |
| 93970 | <1% | 15 | $134.78 | |
| 71100 | <1% | 13 | $121.73 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 55 | $112.73 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 98 | $112.73 |
| 82150 | <1% | 381 | $97.77 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 14 | $81.67 |
| 84550 | <1% | 108 | $78.48 | |
| 83550 | <1% | 405 | $61.74 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 99 | $52.52 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 84 | $52.52 |
| 86803 | <1% | 16 | $49.42 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 442 | $48.45 |
| 84481 | <1% | 107 | $47.90 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 328 | $45.83 |
| 82570 | <1% | 333 | $45.24 | |
| 86038 | <1% | 62 | $28.76 | |
| 87340 | <1% | 88 | $26.58 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 121 | $16.41 |
| 83001 | <1% | 12 | $10.07 | |
| 84156 | <1% | 67 | $8.20 | |
| 86762 | <1% | 12 | $6.60 | |
| 00731 | <1% | 16 | $5.25 | |
| 82950 | <1% | 12 | $2.95 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 333 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 1,010 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 17 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 72 | $0.00 |
| 96367 | 0% | 31 | $0.00 | |
| 82009 | 0% | 31 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 26 | $0.00 |
| J0595 | Injection, butorphanol tartrate, 1 mg | 0% | 16 | $0.00 |
| 29125 | 0% | 15 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 15 | $0.00 |
| 82043 | 0% | 46 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 58 | $0.00 |
| 94761 | 0% | 127 | $0.00 | |
| 90686 | 0% | 20 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 36 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 234 | $0.00 |
| J3490 | Unclassified drugs | 0% | 135 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 13 | $0.00 |
| 94762 | 0% | 26 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.